Tyrosine kinase inhibitorFDA-approvedSecond-line
Alecensa
Generic name: alectinib
How it works
Blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, alectinib achieved an objective response in approximately 50% of patients with ALK-positive NSCLC.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Alectinib's Side Effects Linked to Biotin Deficiency | Lung Cancer | lab-study | — | Source → |
| Combining Alectinib and Cobimetinib to Treat Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Alectinib and Genetic Variations in Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Researchers Explore How Immune Cells Affect Lung Cancer Treatment | Lung Cancer | observational | Progression-free survival on alectinib appeared longer in patients with high than in those with low CD8A expression; however, this difference was not statistically conclusive (HR, 0.49 [95% CI, 0.18-1.35]). | Source → |
| Study of Alectinib as Adjuvant Therapy for Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Alectinib Shows Benefit in Early-Stage Lung Cancer Treatment | Lung Cancer | phase-3 | Patients receiving alectinib had longer DFS versus those who received chemotherapy. | Source → |
| Alectinib Treatment Effective for Some Lung Cancer Patients | Lung Cancer | observational | The median maximum tumor reduction rates were 90.5% for patients with V1, 63.4% for patients with V2, and 98.0% for patients with V3. | Source → |
| Alectinib Therapy for Lung Cancer: A Single Case Study | Lung Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The 3-year progression-free survival rate was 51.5% for brigatinib and 62.1% for alectinib. | Source → |
| Combining Cancer Treatments Increases Risk of Lung Damage | Lung Cancer | observational | — | Source → |
| Researchers Report a Rare Case of Cancer Remission in Stage IV Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Alectinib Shows Longer Survival in Asian Patients with Advanced Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 41.6 months with alectinib versus 11.1 months with crizotinib. | Source → |
| Rare Liver Problem in Lung Cancer Patients Taking Alectinib | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.